Literature DB >> 24768475

Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.

Jason A Roberts1, Mohd H Abdul-Aziz2, Jeffrey Lipman3, Johan W Mouton4, Alexander A Vinks5, Timothy W Felton6, William W Hope7, Andras Farkas8, Michael N Neely9, Jerome J Schentag10, George Drusano11, Otto R Frey12, Ursula Theuretzbacher13, Joseph L Kuti14.   

Abstract

Infections in critically ill patients are associated with persistently poor clinical outcomes. These patients have severely altered and variable antibiotic pharmacokinetics and are infected by less susceptible pathogens. Antibiotic dosing that does not account for these features is likely to result in suboptimum outcomes. In this Review, we explore the challenges related to patients and pathogens that contribute to inadequate antibiotic dosing and discuss how to implement a process for individualised antibiotic therapy that increases the accuracy of dosing and optimises care for critically ill patients. To improve antibiotic dosing, any physiological changes in patients that could alter antibiotic concentrations should first be established; such changes include altered fluid status, changes in serum albumin concentrations and renal and hepatic function, and microvascular failure. Second, antibiotic susceptibility of pathogens should be confirmed with microbiological techniques. Data for bacterial susceptibility could then be combined with measured data for antibiotic concentrations (when available) in clinical dosing software, which uses pharmacokinetic/pharmacodynamic derived models from critically ill patients to predict accurately the dosing needs for individual patients. Individualisation of dosing could optimise antibiotic exposure and maximise effectiveness.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24768475      PMCID: PMC4181663          DOI: 10.1016/S1473-3099(14)70036-2

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  146 in total

1.  Prevention of resistance: a goal for dose selection for antimicrobial agents.

Authors:  G L Drusano
Journal:  Clin Infect Dis       Date:  2003-01-15       Impact factor: 9.079

2.  A comparison of albumin and saline for fluid resuscitation in the intensive care unit.

Authors:  Simon Finfer; Rinaldo Bellomo; Neil Boyce; Julie French; John Myburgh; Robyn Norton
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

Review 3.  Pharmacokinetics and pharmacodynamics of antibiotics in otitis media.

Authors:  W A Craig; D Andes
Journal:  Pediatr Infect Dis J       Date:  1996-03       Impact factor: 2.129

4.  Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.

Authors:  P G Ambrose; D M Grasela; T H Grasela; J Passarell; H B Mayer; P F Pierce
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 5.  Implications of augmented renal clearance in critically ill patients.

Authors:  Andrew A Udy; Jason A Roberts; Jeffrey Lipman
Journal:  Nat Rev Nephrol       Date:  2011-07-19       Impact factor: 28.314

6.  Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.

Authors:  Giuseppe Valenza; Harald Seifert; Sabine Decker-Burgard; Joerg Laeuffer; Ian Morrissey; Reinier Mutters
Journal:  Int J Antimicrob Agents       Date:  2012-01-09       Impact factor: 5.283

7.  Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections.

Authors:  J A Passarell; A K Meagher; K Liolios; B B Cirincione; S A Van Wart; T Babinchak; E J Ellis-Grosse; P G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

8.  Monte Carlo simulations based on phase 1 studies predict target attainment of ceftobiprole in nosocomial pneumonia patients: a validation study.

Authors:  Anouk E Muller; Anne H Schmitt-Hoffmann; Nieko Punt; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2013-02-12       Impact factor: 5.191

9.  Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?

Authors:  Gloria Wong; Scott Briscoe; Syamhanin Adnan; Brett McWhinney; Jacobus Ungerer; Jeffrey Lipman; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2013-09-30       Impact factor: 5.191

10.  Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003.

Authors:  Viktor Y Dombrovskiy; Andrew A Martin; Jagadeeshan Sunderram; Harold L Paz
Journal:  Crit Care Med       Date:  2007-05       Impact factor: 7.598

View more
  226 in total

Review 1.  Understanding PK/PD.

Authors:  Jason A Roberts; Fabio Silvio Taccone; Jeffrey Lipman
Journal:  Intensive Care Med       Date:  2015-09-03       Impact factor: 17.440

Review 2.  [Pharmacokinetics and pharmacodynamics of antibiotic therapy].

Authors:  S Beck; S G Wicha; C Kloft; M G Kees
Journal:  Anaesthesist       Date:  2014-10       Impact factor: 1.041

3.  Model-Optimized Fluconazole Dose Selection for Critically Ill Patients Improves Early Pharmacodynamic Target Attainment without the Need for Therapeutic Drug Monitoring.

Authors:  Indy Sandaradura; Jessica Wojciechowski; Deborah J E Marriott; Richard O Day; Sophie Stocker; Stephanie E Reuter
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

4.  Optimization of Fluconazole Dosing for the Prevention and Treatment of Invasive Candidiasis Based on the Pharmacokinetics of Fluconazole in Critically Ill Patients.

Authors:  J M Boonstra; A G Märtson; I Sandaradura; J G W Kosterink; T S van der Werf; D J E Marriott; J G Zijlstra; D J Touw; J W C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

Review 5.  [Antibiotic stewardship : Measures for optimizing prescription of anti-infective agents].

Authors:  C Lanckohr; H Bracht
Journal:  Anaesthesist       Date:  2018-01       Impact factor: 1.041

Review 6.  Optimising drug dosing in patients receiving extracorporeal membrane oxygenation.

Authors:  Vesa Cheng; Mohd-Hafiz Abdul-Aziz; Jason A Roberts; Kiran Shekar
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

Review 7.  The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.

Authors:  T Tängdén; V Ramos Martín; T W Felton; E I Nielsen; S Marchand; R J Brüggemann; J B Bulitta; M Bassetti; U Theuretzbacher; B T Tsuji; D W Wareham; L E Friberg; J J De Waele; V H Tam; Jason A Roberts
Journal:  Intensive Care Med       Date:  2017-04-13       Impact factor: 17.440

8.  In Vivo Investigation of Antimicrobial Blue Light Therapy for Multidrug-resistant Acinetobacter baumannii Burn Infections Using Bioluminescence Imaging.

Authors:  Yucheng Wang; Olivia D Harrington; Ying Wang; Clinton K Murray; Michael R Hamblin; Tianhong Dai
Journal:  J Vis Exp       Date:  2017-04-28       Impact factor: 1.355

9.  Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients.

Authors:  Joan Antoni Schoenenberger-Arnaiz; Faten Ahmad-Diaz; Mar Miralbes-Torner; Ana Aragones-Eroles; Manuel Cano-Marron; Mercedes Palomar-Martinez
Journal:  Eur J Hosp Pharm       Date:  2019-02-27

10.  Monitoring of Tobramycin Exposure: What is the Best Estimation Method and Sampling Time for Clinical Practice?

Authors:  Yanhua Gao; Stefanie Hennig; Michael Barras
Journal:  Clin Pharmacokinet       Date:  2019-03       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.